ArticleMolecular medicine reports2021
Knockdown of circ‑PVT1 inhibits the progression of lung adenocarcinoma and enhances the sensitivity to cisplatin via the miR‑429/FOXK1 signaling axis.
Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- The emerging role of exosomal circRNAs in modulating apoptotic pathways and overcoming cancer therapy resistance.Discover oncology · 2026Review
- LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target.Molecular cancer · 2026Review
- CircCDK6 Regulates Stemness Maintenance and Cisplatin Resistance in Lung Adenocarcinoma via the Wnt/β-Catenin Signaling Pathway.Cancer management and research · 2026Article
- KY216-tubulin complex captures VASH2 to inhibit NSCLC metastasis.Nature communications · 2025Article
- Integrative Mendelian randomization and spatial transcriptomics analysis reveals causal links between plasma lipidome and non-small cell lung cancer.Discover oncology · 2025Article
- Role of circular RNAs in cancer therapy resistance.Molecular cancer · 2025Review
- The Emerging Roles of CircPVT1 in Cancer Progression.Current pharmaceutical biotechnology · 2025Review
- Circ-NUP98 Promotes Lung Adenocarcinoma Development Through Regulating CBX1 by miR-188-3p.Biochemical genetics · 2024Article
- Circular RNAs in lung cancer: implications for preventing therapeutic resistance.EBioMedicine · 2024Review
- Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance.Cellular and molecular life sciences : CMLS · 2024Review
- circPVT1 Inhibits the Proliferation and Aids in Prediction of the Prognosis of Bladder Cancer.Pharmacogenomics and personalized medicine · 2024Article
- HIF-1-Induced hsa-miR-429: Understanding Its Direct Targets as the Key to Developing Cancer Diagnostics and Therapies.Cancers · 2023Review
- Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1 (Genes & diseases · 2023Review
- Landscape of circular RNAs in different types of lung cancer and an emerging role in therapeutic resistance (Review).International journal of oncology · 2023Article
- Exosomal circular RNA: a signature for lung cancer progression.Cancer cell international · 2022Review
- lncRNA PVT1: a novel oncogene in multiple cancers.Cellular & molecular biology letters · 2022Review
- Circular RNA circ_0005835 promotes promoted neural stem cells proliferation and differentiate to neuron and inhibits inflammatory cytokines levels through miR-576-3p in Alzheimer's disease.Environmental science and pollution research international · 2022Article
- CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals.Molecular cancer · 2022Review
- The emerging role of circular RNAs in drug resistance of non-small cell lung cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the most prevalent cancers in China, and its incidence and morbidity remain high due to various independent factors. Lung adenocarcinoma (ADC) is the most common type of non‑small cell lung carcinoma. Circular RNA plasmacytoma variant translocation 1 (circ‑PVT1) plays an oncogenic role in various types of cancer, but the specific role of circ‑PVT1 in lung ADC has not yet been reported. In the present study, circ‑PVT1 was knocked down in A549 cells and the cell viability, proliferation, migration and invasion were measured via MTT, colony formation, wound healing and Transwell assays, respectively. Then, the cell viability of A549 cells with circ‑PVT1‑knockdown or ‑overexpression was detected after exposure to cisplatin (DDP). After confirming the associations among circ‑PVT1, microRNA (miR)‑429 and forkhead box k1 (FOXK1) using various tools and assays, the cellular functions of A549 cells treated with combined short hairpin (sh)RNA‑circ‑PVT1 and miR‑429 inhibitor/pcDNA3.1‑FOXK1 were tested again. The expression of circ‑PVT1 was found to be increased in lung ADC cells, and shRNA‑circ‑PVT1 led to decreased cell viability, proliferation, migration and invasion. The expression of circ‑PVT1 was higher in A549/DDP cells than that in A549 cells, and the activity of caspase‑3 was also activated by DDP in A549/DDP cells transfected with shRNA‑circ‑PVT1, whereas it was inactivated by DDP in A549 cells transfected with circ‑PVT1 overexpression plasmid. Furthermore, the decreased cell viability, proliferation, invasion and migration induced by shRNA‑circ‑PVT1 could be abated by transfection with miR‑429 inhibitor and pcDNA3.1‑FOXK1. In conclusion, interference of circ‑PVT1 inhibits the progression of lung ADC and enhances its sensitivity to DDP via miR‑429/FOXK1, which may provide a theoretical basis for the use of novel targets in the treatment of lung ADC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.